Evidence map›Paper›PMID 35011280›Full record

ReviewMolecules (Basel, Switzerland)2021

Recent Advances in Polyurethane/POSS Hybrids for Biomedical Applications.

Jan Ozimek, Krzysztof Pielichowski

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jan OzimekDepartment of Chemistry and Technology of Polymers, Cracow University of Technology, Warszawska 24, 31-155 Cracow, Poland.ORCID 0000-0001-8381-8032
Krzysztof PielichowskiDepartment of Chemistry and Technology of Polymers, Cracow University of Technology, Warszawska 24, 31-155 Cracow, Poland.ORCID 0000-0002-7122-201X

Funding

National Science Center 2017/27/B/ST8/01584
6 · The paper itself

Abstract

Advanced organic-inorganic materials-composites, nanocomposites, and hybrids with various compositions offer unique properties required for biomedical applications. One of the most promising inorganic (nano)additives are polyhedral oligomeric silsesquioxanes (POSS); their biocompatibility, non-toxicity, and phase separation ability that modifies the material porosity are fundamental properties required in modern biomedical applications. When incorporated, chemically or physically, into polyurethane matrices, they substantially change polymer properties, including mechanical properties, surface characteristics, and bioactivity. Hence, this review is dedicated to POSS-PU composites that have recently been developed for applications in the biomedical field. First, different modes of POSS incorporation into PU structure have been presented, then recent developments of PU/POSS hybrids as bio-active composites for scaffolds, cardiovascular stents, valves, and membranes, as well as in bio-imaging and cancer treatment, have been described. Finally, characterization and methods of modification routes of polyurethane-based materials with silsesquioxanes were presented.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsBiotechnologyDrug DevelopmentMolecular StructureNanocompositesOrganosilicon CompoundsPolymerizationPolyurethanesAntineoplastic AgentsBiocompatible MaterialsOrganosilicon CompoundspolyhedraloligosilsesquioxanePolyurethanesbiomedical applicationsfunctionalizationhybridspolyurethanePOSS

Identifiers

PMID35011280
PMCPMC8746980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.